2021.04.26 Press release

--To the press -

FRONTEO's "Conversational Dementia Diagnosis Support AI System" Clinical Trials Started

FRONTEO Inc.
Masahiro Morimoto, President and CEO
東京 都 港区 港 南 2-12-23
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) has announced that the clinical trial of "Conversational Dementia Diagnosis Support AI System" has started on April 4. I will.

 

 This study submitted a clinical trial plan notification on March 2021, 3, and the investigation period stipulated by the "Act on Securing Quality, Effectiveness, and Safety of Pharmaceuticals, Medical Devices, etc." (commonly known as the Pharmaceutical Machinery Act) After that, we have started the clinical trial.Toward the start of the clinical trial, we passed the Central IRB on April 12, and a contract with the clinical trial site was signed, and we were able to obtain consent from the patients for clinical trial cooperation today.

 

 FRONTEO has dementia in Japan, such as early detection of dementia and suppression of its aggravation, reduction of medical disparity between regions regarding dementia treatment, and reduction of mental and financial burden on both medical staff and patients. We will advance clinical trials toward the early acquisition of manufacturing approval for this system to help with countermeasures.

 

■ Conversational dementia diagnosis support system  URL: https://lifescience.fronteo.com/aidevice/dementia/
The conversational dementia diagnosis support system (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder (registered trademark: conceptencoder, reading: concept encoder)" between the patient and the doctor. It is a system that can screen for cognitive dysfunction from daily conversation for about 5 minutes.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I will. FRONTEO entered into a business alliance agreement with Kyowa Yakuhin Kogyo Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 10, aiming for early commercialization and early market penetration in the medical field.Patent registration number: Patent No. 2020

 

■ About Concept Encoder URL:https://lifescience.fronteo.com/technology/conceptencoder/

"Concept Encoder (registered trademark: concept encoder, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

 

FRONTEO  URL:https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

 

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc. Segawa

E-mail: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x